Highlights
- FY26 net profit was AUD 33.9 million, with cash reserves of AUD 252.1 million.
- CLINUVEL reported FY26 revenues of AUD 101.2 million in its financial summary.
- In October, the company announced filing of its NEURACTHEL Instant dossier.
- Its 2026 Annual Report outlined SCENESSE and additional development programmes.
Clinuvel Pharmaceuticals develops and distributes therapies for genetic, metabolic and dermatological disorders, centred on melanocortin-based medicines. Clinuvel Pharmaceuticals (ASX:CUV) shares closed at AUD 7.29 on November 18, 2026, down 1.22% for the session. Its 2026 reporting outlined Earnings from commercial products, a substantial cash position and ongoing development activity, including regulatory work concerning NEURACTHEL Instant and research in vitiligo.
SCENESSE Operations and Product Portfolio
CLINUVEL markets SCENESSE, an afamelanotide implant used to prevent phototoxic reactions in adults with erythropoietic protoporphyria. The company describes distribution approvals in Europe, the United States, Canada, Israel and Australia. Patients receive treatment through a specialised healthcare pathway rather than conventional consumer distribution. As a result, reimbursement, specialist centre capacity and the number of eligible treated patients are relevant operational considerations.
The company also describes work involving additional melanocortin therapies, dermatology and photomedicine. Its annual report identifies vitiligo research, work on NEURACTHEL Instant and a Research and Development centre in Singapore. These activities are distinct from the established commercial SCENESSE business: research progress does not itself represent approved sales.
FY26 Earnings, Cash and Investment
CLINUVEL’s financial summary records FY26 revenues, including interest and other income, of AUD 101.2 million and net profit of AUD 33.9 million. Cash reserves were AUD 252.1 million, total Assets AUD 295.1 million and total liabilities AUD 22.2 million. Its financial summary defines cash reserves as cash and cash equivalents plus term deposits. That definition matters when evaluating Liquidity alongside operating receipts and research expenditure.
Reported Operating Cash Flow for FY26 was AUD 39.6 million. The company’s financial statements and annual report provide separate measures for earnings, liquidity and the scale of clinical investment. Profitability from an approved therapy and expenditure on additional products need to be considered independently because the timing and regulatory outcomes of development projects remain uncertain.
October Regulatory and Clinical Updates
In October 2026, CLINUVEL announced that it had filed a dossier for NEURACTHEL Instant. Filing is a regulatory milestone, not equivalent to authorisation or commercial availability. The company’s 2026 annual report also discussed case reports from its CUV105 vitiligo programme, alongside planned subsequent clinical reporting.
The report noted a Notice of Compliance granted by Health Canada in July 2026 for SCENESSE in Canadian patients with erythropoietic protoporphyria. This adds a regulatory market to the approved product’s footprint, although the pace of treatment-centre participation and patient access determines commercial implementation. Research milestones and regulatory decisions should not be treated as assured future product revenue.
Risks and Next Monitoring Points
CLINUVEL faces reimbursement and access requirements in the markets where SCENESSE is approved. Broader development programmes carry clinical, Manufacturing and regulatory risks. Investment in new formulations and indications also requires management to balance programme spending against the established product’s cash generation.
Relevant future disclosures include NEURACTHEL regulatory correspondence, the next reports from the vitiligo programme, patient-access activity and the next half-year financial results. Changes in treatment volumes, operating expenses and cash reserves will help show how the existing commercial base supports the planned product pipeline.
Key Insights
Clinuvel Pharmaceuticals (ASX:CUV) reported FY26 profitability, operating cash generation and sizeable cash reserves while pursuing additional pharmaceutical programmes. SCENESSE remains the established commercial medicine; NEURACTHEL and vitiligo initiatives represent different development and regulatory stages. The next verified disclosures will clarify patient access, expenditure and progress against programme milestones.






Please wait processing your request...